The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.
A. F. List
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
A. Giagounidis
Consultant or Advisory Role - Celgene
Honoraria - Celgene
J. T. Backstrom
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
T. Fu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
P. Fenaux
Honoraria - Celgene
Research Funding - Celgene